Patents Assigned to Eli Lilly and Company
  • Publication number: 20190111039
    Abstract: The present invention provides a method of treating symptoms associated with Androgen Deprivation Therapy comprising administering to a patient in need of such treatment an effective amount of a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 11, 2018
    Publication date: April 18, 2019
    Applicant: Eli Lilly and Company
    Inventors: Charles Thomas BENSON, Rachel Nicole RICHEY, Hannah YU
  • Patent number: 10253041
    Abstract: Phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds of Formula I, formulations containing those compounds, and their use as mutant isocitrate dehydrogenase 1 enzyme inhibitors.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: April 9, 2019
    Assignee: Eli Lilly and Company
    Inventors: Renato A. Bauer, Serge Louis Boulet, Timothy Paul Burkholder, Santiago Carballares Martin, James Ronald Gillig, Raymond Gilmour, Wenceslao Lumeras, Zhipei Wu
  • Patent number: 10253096
    Abstract: The present invention relates to antibodies that bind human T-cell immunoglobulin- and mucin-domain-containing protein-3 (Tim-3), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: April 9, 2019
    Assignee: Eli Lilly and Company
    Inventors: Yi Zhang, Yang Shen, Carmine Carpenito, Yiwen Li
  • Publication number: 20190091409
    Abstract: Sensing systems are disclosed for determining the relative rotational movements of members of a medication delivery device which are proportional to the amount of a dose set and delivered by the medication delivery device. The sensing system comprises a first sensor component secured to a first member and a second sensor component secured to a second member. During dose setting, the second member is coupled to a third member which rotates relative to the first member in proportion to the dose set. During dose delivery, the second member is coupled to a fourth member which rotates relative to the first member in proportion to the dose delivered. The sensing system separately detects the relative rotational positions of the first and second sensor components during dose setting and dose delivery, and provides outputs used to determine the amounts of the set and delivered doses. The sensing system outputs this information to a controller which determines the amount of the dose set and delivered.
    Type: Application
    Filed: March 17, 2017
    Publication date: March 28, 2019
    Applicant: Eli Lilly and Company
    Inventor: Roy H. Byerly
  • Patent number: 10238656
    Abstract: The present invention provides preparation of medicaments for use in treating and methods of treating non-small cell lung cancer in a patient comprising: [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, in combination, as further described herein, with an anti-VEGFR2 antibody, preferably, ramucirumab.
    Type: Grant
    Filed: February 19, 2015
    Date of Patent: March 26, 2019
    Assignee: Eli Lilly and Company
    Inventor: Edward Michael Chan
  • Patent number: 10227310
    Abstract: The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: March 12, 2019
    Assignee: Eli Lilly and Company
    Inventors: Christopher Stanley Galka, Erik James Hembre, Nicholas Allan Honigschmidt, Maria Angeles Martinez-Grau, Gema Ruano Plaza, Almudena Rubio, Stacy Jo Keding, Daryl Lynn Smith
  • Patent number: 10213487
    Abstract: The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: February 26, 2019
    Assignee: Eli Lilly and Company
    Inventors: Sankaram Mantripragada, Claude A. Piche, Jo Jan Filip Van Betsbrugge
  • Patent number: 10214586
    Abstract: The present invention relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: February 26, 2019
    Assignee: Eli Lilly and Company
    Inventors: Dale Lincoln Ludwig, Marshall Davenport Snavely, Yiwen Li, Juqun Shen, Vera Molkenthin
  • Patent number: 10196385
    Abstract: The present invention provides compounds of the Formula below wherein R, R1-R3 are as described herein; methods of treating patients for diabetes using the compounds, and processes for preparing the compounds.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: February 5, 2019
    Assignee: Eli Lilly and Company
    Inventors: Zhi Long Hu, Lian Zhu Liu, Tianwei Ma, Haizhen Zhang, Jingye Zhou
  • Patent number: 10189818
    Abstract: The disclosure herein includes 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile (S)-lactate monohydrate that inhibits Chk1/2 and is useful in the treatment of cancer.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: January 29, 2019
    Assignee: Eli Lilly and Company
    Inventor: Alessandra B. Ennett-Shepard
  • Patent number: 10179209
    Abstract: A needle covering system for a needle of a syringe. A boot of the system defines a contaminant-proof pocket for the needle. A sealing ring portion of the boot forms a seal with a support portion of the syringe. A body of the boot is collapsible to allow movement of a needle pierceable end portion of the boot toward the sealing ring portion for a tip of the needle to pass through the boot end portion for an injection. A securement collar of the system presses the sealing ring against the support portion of the syringe and is a remnant portion of a protective shell.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: January 15, 2019
    Assignee: Eli Lilly and Company
    Inventors: Jesse Arnold Fourt, Jeremy Christopher Koehler
  • Patent number: 10172922
    Abstract: The invention is a composition of human insulin or insulin analog that includes treprostinil and that has faster pharmacokinetic action than commercial formulations of existing insulin analog products.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: January 8, 2019
    Assignee: Eli Lilly and Company
    Inventors: Michael Edward Christe, Thomas Andrew Hardy
  • Patent number: 10138244
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, for use as a human PDE1 inhibitor.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: November 27, 2018
    Assignee: Eli Lilly and Company
    Inventors: Mark David Rekhter, Qing Shi
  • Patent number: 10118001
    Abstract: A cap assembly mountable to a rigid shield around a needle of a syringe. The cap assembly includes a gripper component and a base cap. The gripper component includes a support frame and a liner that is deformable when sandwiched between the support frame and the rigid shield. When the base cap is installed to the gripper component during manufacture, and with the rigid shield disposed in a bore of the gripper component in any rotational orientation relative thereto, the liner is held by the support frame so as to be deformed against and grip the rigid shield for shield removal purposes so as to allow for removal of the rigid shield from around the needle.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: November 6, 2018
    Assignee: Eli Lilly and Company
    Inventors: Jesse Arnold Fourt, James R. Yurchenco, Remy O'Leary Pieron
  • Patent number: 10112951
    Abstract: The present invention provides a compound of Formula I: useful for treating chronic kidney disease and diabetic kidney disease.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: October 30, 2018
    Assignee: Eli Lilly and Company
    Inventor: Mark David Rekhter
  • Publication number: 20180291093
    Abstract: Bispecific antibodies are provided that bind Calcitonin Gene Related Peptide (CGRP) and Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CGRP and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease and Ulcerative Colitis, Psoriatic Arthritis (PsA) and ankylosing spondylitis (AS).
    Type: Application
    Filed: October 30, 2015
    Publication date: October 11, 2018
    Applicant: Eli Lilly and Company
    Inventors: Robert Jan Benschop, Rohn L Millican, JR., Barrett Allan, Catherine Brautigam Beidler
  • Patent number: 10093651
    Abstract: The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: October 9, 2018
    Assignee: Eli Lilly and Company
    Inventors: Christopher Stanley Galka, Erik James Hembre, Nicholas Allan Honigschmidt, Maria Angeles Martinez-Grau, Gema Ruano Plaza, Almudena Rubio
  • Patent number: 10093727
    Abstract: Antibodies are provided that specifically bind seven human ELR+ CXC chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: October 9, 2018
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Kristine Kay Kikly, Beth Ann Strifler, Derrick Ryan Witcher, Sudhakar Reddy Chintharlapalli
  • Patent number: 10081625
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treatment of neurodegenerative diseases and disorders, such as Alzheimer's disease.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: September 25, 2018
    Assignee: Eli Lilly and Company
    Inventors: Nicolas Jacques Francois Dreyfus, Peter James Lindsay-Scott
  • Patent number: 10080758
    Abstract: The present invention provides a tosylate salt of N-[3-[(4aR,7aS)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide.
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: September 25, 2018
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Craig Daniel Wolfangel